Key Takeaways United Therapeutics surged 33% after positive results from the TETON-2 Tyvaso study in IPF.Tyvaso showed superiority over placebo in lung function after 52 weeks with consistent safety.UTHR aims to expedite review by meeting the FDA this year ahead of TETON-1 results in 2026.Shares of United Therapeutics (UTHR) surged 33% on Tuesday after it announced positive top-line results from the late-stage TETON-2 study evaluating the nebulized version of Tyvaso (treprostinil) in adult patients with idi ...